Caristo Diagnostics
Caristo Diagnostics is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants with Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT trial)
Sponsor NewAmsterdam Pharma B.V.
- Start (EU)
- Latest update
- Estimated end
J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Orticumab in Participants with Prior Myocardial Infarction who have Elevated Coronary Inflammation Based on Fat Attenuation Index (FAI) Score Assessed by Coronary Computed Tomography Angiography (CCTA)
Sponsor Abcentra LLC
- Start (EU)
- Latest update
- Estimated end
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Caristo Diagnostics?
The 2026-10-09 snapshot links Caristo Diagnostics to 4 distinct CTIS trials. Recorded services include Imaging, CT-scan analysis vendor, Imaging Analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Caristo Diagnostics?
The most frequently recorded therapeutic areas are Cardiology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Caristo Diagnostics conducted?
The linked trials record locations in 18 countries, including Czechia, Spain, Hungary, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where Caristo Diagnostics delivered services.
What can this page tell me about Caristo Diagnostics's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Caristo Diagnostics. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Caristo Diagnostics Limited
- Caristo Diagnostics Ltd